Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.50 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1531517 | 0.88 | CA12 (0.51) | NPFFR1NPFFR2CA12CA1CA2 | |
| SCHEMBL3210914 | 0.86 | CYP1A2 (0.51) | KDM4EKMT2ANPFFR1NPFFR2CYP1A2 | |
| SCHEMBL1531618 | 0.84 | CYP1A2 (0.51) | NPFFR1NPFFR2CA12CA1CA2 | |
| SCHEMBL6027076 | 0.84 | KDM4E (0.49) | KDM4EKMT2ANPFFR1NPFFR2CYP1A2 | |
| SCHEMBL652551 | 0.84 | KDM4E (0.49) | KDM4EKMT2ANPFFR1NPFFR2CYP1A2 | |
| SCHEMBL11562851 | 0.84 | KMT2A (0.53) | KDM4EKMT2ANPFFR1NPFFR2CYP1A2 | |
| SCHEMBL2542108 | 0.83 | CYP1A2 (0.50) | KDM4ENPFFR1NPFFR2CA12CA1 | |
| SCHEMBL9311052 | 0.82 | KMT2A (0.47) | KDM4EKMT2ACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL782996 | 0.82 | CYP1A2 (0.51) | KMT2ANPFFR1NPFFR2CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL7839095 | 0.81 | KMT2A (0.46) | KDM4EKMT2ACYP1A2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040047-A1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2021-02-11 | — | — | US | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-2137179-B1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| CN-104031054-A | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARM INC | 2014-09-10 | — | — | CN | disclosed |
| CN-1585772-B | chemokine receptor antagonists and methods and uses thereof | MILLENNIUM PHARM INC | 2014-06-04 | — | — | CN | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2586778-A2 | Pyridazinone derivatives useful as glucan synthase inhibitors | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-1999031058-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-06-24 | — | — | WO | disclosed |
| WO-1996002250-A1 | HALOPERIDOL ANALOGS AND THE USE THEREOF | ACEA PHARMACEUTICALS INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0594593-A1 | THERAPEUTICALLY USEFUL HETEROCYCLIC INDOLE COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1994-05-04 | — | — | EP | disclosed |
| US-5302599-A | Administering for central nervous system and cardiovascular disorders | THE UPJOHN COMPANY (US) | 1994-04-12 | — | — | US | disclosed |
| WO-1991013872-A1 | THERAPEUTICALLY USEFUL HETEROCYCLIC INDOLE COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-09-19 | — | — | WO | disclosed |
| EP-0121972-B1 | N-ARYL-ALPHA-AMINO-CARBOXAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-05-24 | — | — | EP | disclosed |
| EP-0121972-A2 | N-aryl-alpha-amino-carboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-10-17 | — | — | EP | disclosed |
| US-4179569-A | ANALGESIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-4051248-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, NEUROLEPTIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040047-A1 | NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION | VDAC1, VDAC2, VDAC3 | KDM4E 3696/4885KMT2A 3775/4885NPFFR1 1645/4885 |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | KDM4E 4876/4885KMT2A 4568/4885NPFFR1 248/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | KDM4E 4876/4885KMT2A 4568/4885NPFFR1 248/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | KDM4E 4876/4885KMT2A 4568/4885NPFFR1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.